A graph from the published study.

Metacurum study

Preclinical data showing that MetaCurum’s antibody reduces tumor growth in prostate cancer in a dose-dependent model.
Filtyp:png
Licens:Media use
Storlek:347kb
Notified logoPowered by Notified